top of page


Teva acquires BioXcel neuroscience assets including BXCL501 for up to $125 million
Teva has acquired worldwide rights to BioXcel's BXCL501 neuroscience programme and approved IGALMI product in an asset transaction worth up to $125 million.

nuaxia
Oct 282 min read


Jaguar LAA acquires Johnson & Johnson Laminar assets for atrial fibrillation programme
Jaguar LAA has acquired assets from Johnson & Johnson related to the Laminar left atrial appendage closure programme, creating a newly independent medical-device company focused on advancing the technology.

nuaxia
Sep 152 min read
bottom of page